REGISTER NOW: 2023 Preview Webinar
Thursday 26 January, 3pm GMT | 10am EST
At the end of a year that for most in the biopharma industry went from bad to worse, what's the outlook for 2023? Will there be an improvement in IPOs and dealmaking?
In this webinar, we will discuss the issues set to shape the biopharma industry over the next 12 months. Following the recent release of the 2023 Preview Report, Evaluate Vantage's Amy Brown and Edwin Elmhirst will take a deeper dive into the data from 2022 and discuss the key factors influencing the outlook for the coming year.


  • Innovation and regulation: what developments lie ahead?
  • Growing biopharma's top line: which drugs and companies will lead the pack?
  • Something new: what are the R&D projects and potential launches to look out for?
  • Positive signs: where are they coming from?

Your Hosts:

Amy Brown
Amy Brown,
Deputy Editor, Evaluate Vantage
Edwin Elmhirst
Edwin Elmhirst,
Data Journalist, Evaluate Vantage